Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Supreme Court Docket Includes Four Cases Impacting Pharma Industry

Executive Summary

Helsinn v. Teva and Merck v. Albrecht directly involve pharma firms while another case addresses America Invents Act. Solicitor General to weigh in on two other cases. Petitions pending on Maryland pricing law, Amgen PCSK9 suit.

You may also be interested in...



Restasis Patent Review Back On Track As Federal Circuit Quashes Mohawk Tribe's Sovereign Immunity Claim

Appeals court says inter partes review is more like an agency enforcement action than a civil suit and thus tribal immunity does not apply to the proceeding; PTAB now to determine patentability of Restasis patents.

Can Patents Be Wiped Out Because Of A Litigator's Misconduct? Regeneron Asks Supreme Court

Regeneron challenges Federal Circuit finding that withholding information in discovery constitutes inequitable conduct; district judge orders firm to pay Merus $10.5m in attorneys' fees and costs.

Does Sale Of Confidential Invention Prevent Its Patenting? US Supreme Court Will Review

Helsinn v. Teva challenges whether inventor's sale of an invention to a third party that must in turn keep the invention secret makes it unpatentable; America Invents Act amended "on-sale" bar provision.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB002458

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel